Austrade invites Australian businesses involved in research and innovation across the life sciences, medical, and pharmaceutical sectors to join the 2018 Life Sciences Mission to China.
Mission highlights include attending the China BioMed Innovation and Investment Conference 2018, visiting Suzhou BioBay, and attending a Clinical Trials Seminar with Zhongguancun Life Science Park in Beijing. There will be valuable opportunities to build connections with key customers and contacts, gain insights from senior company and regulatory representatives across the Chinese health sector, and promote Australian health capabilities to over 2,000 conference attendees.
Identified by President Xi Jinping as a growth area in his “Made in China 2025” Plan, China possesses the second largest pharmaceutical market worldwide. Ongoing regulatory reform of the State Drug Administration (SDA), supportive R&D infrastructure, and growing biotechnology and medical innovation and investment have seen China emerge as a prime market for pharmaceutical and healthcare companies.